Ampersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million. Based in Lawrence, Massachusetts, Nexcelom is a provider of automated cell counting solutions. WELLESLEY, Mass.

Lawrence, Massachusetts-based Nexcelom Bioscience, a provider of cell counting and analysis products for biomedical research and the biopharma industry, has secured an undisclosed amount of funding.

ATLANTA, April 1, 2019 /CNW/ -- Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high ...

WELLESLEY, Mass., June 25, 2021 /PRNewswire/ -- Ampersand Capital Partners announced today that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider ...

PerkinElmer Inc. (PKI) has agreed to acquire Nexcelom Bioscience for a total cash consideration of $260 million. The acquisition is expected to close in Q2. PerkinElmer serves the diagnostics, life ...

Expertise in Automated Cell Counting and Analysis In 2003, the founders of Nexcelom introduced the CP2, a convenient tool to assist with manual cell counting. According to Dr. Jean Qiu, founder and ...

Nexcelom Bioscience is a biotechnology company composed of biological scientists, software developers, and mechanical engineers who are dedicated to advancing the field of biomedical research. It is a ...

Nexcelom Bioscience LLC has announced it continues to expand its line of Cellometer automated cell counters with the launch of the Cellometer Auto X4. The Auto X4 is a fluorescence-assisted cell ...

Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated ...

The Cellaca™ MX utilizes Nexcelom's innovative cellular analysis technology for accurate cell sample concentration, viability and morphology measurements. Features of the Cellaca™ MX include: ...